<?xml version="1.0" encoding="UTF-8" ?>

    <journal>
    <language>en</language>
    <journal_id_issn>2008-2835</journal_id_issn>
    <journal_id_issn_online>2008-4625</journal_id_issn_online>
    <journal_id_pii></journal_id_pii>
    <journal_id_doi></journal_id_doi>
    <journal_id_isnet></journal_id_isnet>
    <journal_id_iranmedex>276</journal_id_iranmedex>
    <journal_id_magiran>5669</journal_id_magiran>
    <journal_id_sid>11181</journal_id_sid>
    <pubdate>
	    <type>gregorian</type>
	    <year>>2021</year>
	    <month>>October-December</month>
	    <day></day>
    </pubdate>
    <volume>13</volume>
    <number>4</number>
    <publish_type>online</publish_type>
    <publish_edition>1</publish_edition>
    <article_type>fulltext</article_type>
    <articleset>

<article>
	<language>en</language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed>34900144</article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	<title_fa></title_fa>
	<title>A Cross-Sectional Study for Evaluation of KRAS and BRAF Mutations by Reverse Dot Blot, PCR-RFLP, and Allele-Specific PCR Methods Among Patients with Colorectal Cancer</title>
	<subject_fa></subject_fa>
	<subject></subject>
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; genes are the biomarkers in Colorectal Cancer (CRC) which play prognostic and predictive roles in CRC treatment. Nowadays, the selection of rapid and available methods for studying &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; mutations in anti-EGFR therapy of patients suffering from CRC plays a significant role. In this study, the mutations of these two oncogenes were evaluated by different methods.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; This study was performed on 50 Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks of patients diagnosed with colorectal cancer. After DNA extraction, &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; gene mutations were evaluated using reverse dot blot, and results were compared with PCR-RFLP and allele-specific PCR for &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; mutations, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; KRAS&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; gene mutations were detected in 42% of patients, of which 30% were in codon 12 region, and 12% in codon 13. The most frequent mutations of &lt;em&gt;KRAS&lt;/em&gt; were related to G12D and 10% of patients had &lt;em&gt;BRAF&lt;/em&gt; mutated genes. &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;The type of &lt;em&gt;KRAS&lt;/em&gt; gene mutations could be evaluated by reverse dot blot method. &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;In&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; general, the results of PCR-RFLP and allele-specific PCR were similar to the findings by reverse dot blot method.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; These findings suggest that PCR-RFLP and allele-specific PCR methods are suitable for screening the presence of the mutations in &lt;em&gt;KRAS&lt;/em&gt; and &lt;em&gt;BRAF&lt;/em&gt; oncogenes. In fact, another method with more sensitivity is needed for a more accurate assessment to determine the type of mutations. Due to higher speed of detection, reduced Turnaround Time (TAT), and possible role of some &lt;em&gt;KRAS&lt;/em&gt; point mutations in overall survival, reverse dot blot analysis seems to be an optimal method.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Allele-Specific PCR, BRAF, Colorectal neoplasms, KRAS, PCR-RFLP, Reverse dot blot</keyword>
	<start_page>183</start_page>
	<end_page>191</end_page>
	<web_url>https://www.ajmb.org/En/Article.aspx?id=40475</web_url>
    <pdf_url>https://www.ajmb.org/PDF/En/FullText/40475.pdf</pdf_url>
	<author_list><author><first_name>Fatemeh</first_name><middle_name></middle_name><last_name>Sheikhsofla</last_name><suffix></suffix><affiliation>Department of Cellular and Molecular Biology, University of Mazandaran, Mazandaran, Iran</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>71808</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Behzad</first_name><middle_name></middle_name><last_name>Poopak</last_name><suffix></suffix><affiliation></affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>71809</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Sajjad</first_name><middle_name></middle_name><last_name>Firuzyar</last_name><suffix></suffix><affiliation>Razi Vaccine and Serum Research Institute of Karaj, Karaj, Iran</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>71810</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Fatemeh</first_name><middle_name></middle_name><last_name>Roudbari </last_name><suffix></suffix><affiliation>Department of Virology, University of Mazandaran, Mazandaran, Iran</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>71811</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author><author><first_name>Mojtaba</first_name><middle_name></middle_name><last_name>Ghadiany</last_name><suffix></suffix><affiliation>Department of Hematology and Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation><first_name_fa></first_name_fa><middle_name_fa></middle_name_fa><last_name_fa></last_name_fa><suffix_fa></suffix_fa><email></email><code>71812</code><coreauthor></coreauthor><affiliation_fa></affiliation_fa></author></author_list>
</article>

</articleset>
</journal>

